Talaris Therapeutics to Present at the Jefferies Healthcare Conference
Get Alerts TALS Hot Sheet
Join SI Premium – FREE
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.
A live webcast of the fireside chat will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 30 days.
About Talaris TherapeuticsTalaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media ContactLisa RaffenspergerTen Bridge Communications[email protected](617) 903-8783
Investor ContactChris BrinzeyICR Westwicke[email protected](339) 970-2843
Source: Talaris Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SkyBlue Cinematix Opens Its European Gateway in Germany — Appoints Sofia Torres Martinez to Lead 10 Markets Across Northern & Western Europe
- The World's Most Powerful Magnetic Actuator Is Flight-Ready as Portal Space Systems Unveils Starburst-1
- SkyBlue Cinematix Opens Its European Gateway in Germany — Appoints Sofia Torres Martinez to Lead 10 Markets Across Northern & Western Europe
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share